|
| |
AvigenAvigen is a leader in the development of gene therapy products derived from adeno-associated virus ("AAV") for the treatment of inherited diseases. Avigen's proposed gene therapy products are designed for in vivo administration to achieve the production of therapeutic proteins within the body. Avigen has honed it's strategic focus on developing a broad-based proprietary gene delivery technology, AAV vector. Avigen believes AAV vectors can be used to deliver genes for the treatment of hemophilia, thalassemia, hereditary emphysema and Gaucher's disease.
| Contact Details: |
| 1301 Harbor Bay Parkway |
| Alameda |
| |
| 94502 |
| United States of America |
| Tel: | 510 748 7150 |
| Fax: | 510-748-7155 |
| Email: | info@avigen.com |
| WWW: | www.avigen.com/
|
| |
Recent Publications by Avigen: |  |
Cross-species comparisons of the pharmacokinetics of ibudilast.
To enable clinical development of ibudilast for new indications, its... | 26th September, 2009
| Research and Development, Avigen, Inc., Alameda, CA, USA.
| Xenobiotica. 2009 Sep 24.
DOI Direct Link |
Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.
AV513 is a select fucoidan, a sulfated polysaccharide of botanical origin.... | 12th March, 2008
| Research and Development, Avigen, Alameda, CA 94502, USA.
| Blood. 2008 Jan 15;111(2):672-9. Epub 2007 Oct 31.
DOI Direct Link |
The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain.
Controlling neuropathic pain is an unmet medical need and we set out to... | 8th January, 2008
| Department of Preclinical Development Avigen Inc. Alameda, CA USA.
| Neuron Glia Biol. 2006 Nov;2(4):279-91.
DOI Direct Link |
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.
Paclitaxel is a commonly used cancer chemotherapy drug that frequently... | 1st September, 2007
| Department of Psychology & the Center for Neuroscience, University of
| Brain Behav Immun. 2007 Jul;21(5):686-98. Epub 2006 Dec 15.
DOI Direct Link |
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
Hemophilia A, a deficiency of functional coagulation factor VIII (FVIII),... | 19th August, 2007
|
| Blood. 2006 Jul 1;108(1):107-15. Epub 2006 Mar 7.
DOI Direct Link |
→View more Avigen research publications. |
Press Releases on Avigen:
|
 |
| Adamas Pharmaceuticals Expands Management Team; Names Michael D. Coffee and Amy K. Patick to Executive Positions |
25th August, 2009 |
Adamas Pharmaceuticals, Inc. |
-- ADS-8703, a proprietary fixed-dose combination for the symptomatic
treatment of dementia.
About Mr. Coffee and Dr. Patick
Mr. Coffee brings more than 30 years sales, marketing and
|
| Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders |
27th March, 2009 |
Biotechnology Value Fund, L.P. |
Concurs with Avigen's decision to return capital to stockholders through liquidation
A decisive victory for stockholder democracy
SAN FRANCISCO, March 27 /PRNewswire/ -- Biotechnology Value
|
| Leading Advisory Firm, PROXY Governance, Recommends Avigen Shareholders Vote on GOLD Card to Remove Incumbent Directors and Elect BVF's Stockholder-Oriented Nominees |
23rd March, 2009 |
Biotechnology Value Fund, L.P. |
NEW YORK, March 23 /PRNewswire/ -- Biotechnology Value Fund, L.P. ("BVF") today announced that PROXY Governance, widely recognized as a leading independent proxy advisory firm, has
|
| Empirical Search Strategies Seeks Downside Protection Option at Avigen, Inc. |
20th March, 2009 |
Empirical Search Strategies, L.P. |
CHICAGO, March 20 /PRNewswire/ -- Empirical Search Strategies, LP. ("ESS"), the beneficial owner of approximately 2.3% of the Avigen, Inc.'s (Nasdaq: AVGN) outstanding common stock,
|
| BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share |
23rd January, 2009 |
BVF Acquisition LLC |
NEW YORK, Jan. 23 /PRNewswire/ -- BVF Acquisition LLC (the "Purchaser"), a wholly owned subsidiary of Biotechnology Value Fund, L.P. ("BVF"), announced today that it has commenced
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 415 times since April 2007, the link to the organisation's website has been followed 69 times Search for more companies in Alameda Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Avigen |
